Friday, January 4, 2019
JMP reiterates Outperform on Esperion after European agreement
JMP Securities analyst Jason Butler reiterated an Outperform rating and $153 price target on Esperion Therapeutics after the company announced a European commercialization agreement with Daiichi Sankyo for bempedoic acid and the BA/ezetimibe fixed dose combination. The analyst views this deal as “strong,” and sees Daiichi Sankyo as a compelling strategic fit “given its established commercial infrastructure and success in cardiovascular diseases in the region.”
https://thefly.com/landingPageNews.php?id=2844005
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.